Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMarvel Biosciences Corp

Marvel Biosciences Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.11 CAD -0.01 ( 4.35%)
Last update at 2026-11-04T18:29:00Z
VOLUME
44806
Market Cap
9.77M

Momentum Score

…

Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.11
Low
0.12
High
52 Week Price Range
0.07
Low
0.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Marvel Biosciences Corp (MRVL.V) is limited; company disclosures and online materials identify it as an early-stage biosciences company but provide few operational details. Long-term growth may depend on successful development or licensing of its research assets, partnerships, and access to capital, which could support value creation for investors seeking exposure to early-stage biotech.

Key risks include sparse disclosure, development and regulatory execution risk typical of early-stage life-science companies, potential need for dilutive financing, and low liquidity on its exchange listing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.12
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-380.30%
Net Debt
2.18M
ROCE
31.17%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Income before tax -2.21M -1.65M -2.29M -2.55M -3.04M
Net income -2.21M -1.65M -2.29M -2.55M -3.04M
Selling general administrative 0.92M 0.91M 1.41M 1.17M 1.25M
Gross profit -0.55M -0.30M -0.89M -1.38M -0.61M
Reconciled depreciation - - 0.00M 0.00M 0.00M
Ebit - - - -2.51M -1.25M
Ebitda - - - -2.55M -1.10M
Operating income -1.25M -1.27M -2.25M -2.55M -1.10M
Interest expense 0.27M 0.11M 0.03M - 0.00M
Interest income 0.00M 0.00M - 0.00M 0.00M
Net interest income -0.27M -0.11M -0.04M -0.00M -0.00M
Income tax expense - - - - -0.15M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.25M 1.27M 2.25M 2.55M 1.10M
Cost of revenue 0.55M 0.30M 0.89M 1.38M 0.61M
Total other income expense net -0.70M -0.26M -0.00M -0.00M -1.94M
Net income from continuing ops -2.21M -1.65M -2.29M -2.55M -3.04M
Net income applicable to common shares - - - -2.55M -3.04M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total assets 0.33M 0.49M 0.67M 0.91M 2.47M
Other current assets - - - 0.25M 0.02M
Total liab 4.33M 3.32M 2.39M 0.72M 0.11M
Total stockholder equity -4.01M -2.83M -1.72M 0.20M 2.36M
Other current liab - - - 0.03M -
Common stock - - - 6.86M 6.46M
Capital stock 8.46M 7.58M 7.13M 6.86M 6.46M
Retained earnings -12.91M -10.70M -9.05M -6.76M -4.20M
Other liab - - - -0.00M -
Cash 0.13M 0.35M 0.56M 0.59M 2.39M
Total current liabilities 4.33M 1.61M 1.39M 0.72M 0.11M
Net debt 2.18M 1.36M 0.44M - -
Short long term debt 2.31M - - - -
Other stockholder equity - - - -0.03M -
Property plant equipment - - - - 0.00M
Total current assets 0.33M 0.49M 0.67M 0.91M 2.47M
Net tangible assets - - - 0.20M 2.36M
Net receivables - - - 0.06M 0.06M
Long term debt - 1.71M 1.00M - -
Accounts payable 1.50M 1.35M 1.21M 0.26M 0.00M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Investments - - - 0.00M 0.38M
Change to liabilities - - - 0.61M -0.08M
Total cashflows from investing activities - - - - 0.38M
Net borrowings 0.00M 0.50M - - -0.02M
Total cash from financing activities 0.93M 0.97M 1.30M 0.39M 3.16M
Change to operating activities - - - -0.25M -0.04M
Net income -2.21M -1.65M -2.29M -2.55M -3.04M
Change in cash -0.22M -0.21M -0.04M -1.80M 2.17M
Begin period cash flow 0.35M 0.56M 0.59M 2.39M 0.22M
End period cash flow 0.13M 0.35M 0.56M 0.59M 2.39M
Total cash from operating activities -1.15M -1.18M -1.33M -2.19M -1.37M
Issuance of capital stock 1.02M 0.50M 0.27M 0.42M 3.18M
Depreciation - - 0.00M 0.00M 0.00M
Other cashflows from financing activities - - - -0.03M -0.18M
Change to netincome - - - - 1.78M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.29M 0.18M 0.88M 0.36M -0.11M
Stock based compensation 0.08M 0.08M 0.08M - -
Other non cash items 0.62M 0.21M - - 1.78M
Free cash flow -1.15M -1.18M -1.33M -2.19M -1.37M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
MRVL
Marvel Biosciences Corp		 -0.01
4.35%		 0.11 - - - 226.82 -1.39
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 -
NRX
NurExone Biologic Inc.		 -0.03
5.00%		 0.47 - 6.90 - 15.26 -7.24
MIR
MedMira Inc		 -0.01
9.09%		 0.05 - - 223.37 - -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 -58.16

Profile*

Marvel Biosciences Corp

Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.

505 8th Avenue S.W., Calgary, AB, Canada, T2P 1G2

403 770 2469

https://marvelbiotechnology.com

Name Title Year Born
Mr. J. Roderick Matheson Pres, CEO & Exec. Chairman NA
Dr. Mark Williams M.B.A., Ph.D. Chief Science Officer & Director 1972
Mr. Harpreet Nijjar C.M.A., CPA Chief Financial Officer 1988
Ms. Jacqueline Groot Corp. Sec. NA
Mr. J. Roderick Matheson Executive Chairman & CEO NA
Dr. Mark Williams M.B.A., Ph.D. President, Chief Science Officer & Director 1972
Ms. Jacqueline Groot Corporate Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.34
+14.45%
OMG
CAD 1.70
+13.76%
ARTG
CAD 39.54
+12.59%
DSV
CAD 10.83
+12.58%
TLRY
CAD 4.17
+12.10%
DRUG
CAD 25.95
-30.02%
HUT
CAD 69.16
-22.20%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.70
-15.62%
VET
CAD 15.04
-13.31%

Equity Sectors*

  • Basic Materials

    +4.80%

  • Communication Services

    +2.78%

  • Consumer Cyclical

    +2.82%

  • Consumer Defensive

    +0.74%

  • Energy

    -4.92%

  • Financial Services

    +2.47%

  • Healthcare

    -0.30%

  • Industrials

    -0.38%

  • Real Estate

    +1.75%

  • Technology

    +0.82%

  • Utilities

    +1.29%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…